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It is estimated there are thousands of combinations of drugs, which may generate various adverse drug events, 
including drug interactions (DI). To assess the contribution of pharmacist to identification and management of DI 
in an intensive care unit (ICU). A longitudinal study was conducted in the ICU of a private hospital in the city of 
Aracaju-SE, between 2008 and 2009. The prevalence and clinical relevance of DI was assessed by two clinical 
pharmacists. Demographic data and clinical information of patients hospitalized in the period of the study were 
obtained from medical records. At the end of the study 137 medical records were analyzed, with a predominance 
of female patients (55.4%), average age of 66 (±7.0) years. 6,085 prescriptions were collected during the study 
period, in which 2,455 drugs prescribed. Of these, 175 prescriptions contained clinically relevant DI, 178 of 
moderate severity and 35 of major severity, 213 DI in total.  The clinical pharmacists prepared reports for the 
physicians, which enabled the reduction of 40% of all DI. Data from this study suggest that pharmacist’s 
contribution may have reduced the incidence of DI, providing more familiarity of physicians on clinically 
relevant information and improving the quality of prescriptions in the ICU. 
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INTRODUCTION 
 
In the last century, adverse events associated with the 
use of medicines became a major public health problem 
involving patients and health professionals (Almeida et al., 
2007). Among the adverse events, 30% are drug interactions (DI) 
(Grizzle et al., 2007), which account for approximately 3% of 
hospital admissions in the United States (Mcdonnell, Jacobs, 
2002; Peyriere, 2003). In the same country, the study of Aparasus 
et al. (2007) showed that over 11% of patients experience 
symptoms associated with DI, which led to increase of health 
care costs. According to Lapi et al. (2010), it is estimated that 
there are more than 100,000 combinations of drugs, which may 
be responsible for several adverse drug events. Hammes et al. 
(2008) defined DI as a specific type of adverse event that occurs 
when the effects of a drug are altered by the presence of another. 
Although their results can be both positive and negative,   DI  are 
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often unpredictable and undesirable in pharmacotherapy. Despite 
advances in technology and information provided by health 
authorities to prevent clinically significant DI, hundreds of millions 
of these events occur annually, affecting millions of patients 
(Almeida et al., 2007).  As for the prevalence of DI, their 
occurrence within the hospital is highlighted, since patients are 
generally under multiple drug therapy (Becker et al., 2006). In the 
hospital, the Intensive Care Unit (ICU) provides factors that create 
a favorable situation for DI occurrence (Reis, Cassiani, 2011; 
Rossignoli et al., 2006). Among these factors, it is possible to 
highlight the use of medicines with narrow therapeutic index, the 
presence of patients with organ failure, especially kidneys and liver. 
Furthermore, at ICU there is a high frequency of elderly patients 
with pharmacokinetic and pharmacodynamics alterations common 
to the age (Lima, Cassiani, 2009). The study of DI becomes an 
important tool to optimize the therapeutic regimen, which may 
contribute to the safety, effectiveness and quality of 
pharmacotherapy in the ICU (Reis, Cassiani, 2011; Rossignoli et 
al., 2006). Thus, it is essential that health professionals, such as 
pharmacists, are able to clinically assess possible DI, collaborating 
with the health staff and developing strategies for the management  
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of patients (Abarca et al., 2004; Saverno et al., 2009). Thus, this 
study aimed to assess the pharmacist’s contribution to 
identification and management of DI in ICU of a private hospital. 
 
METHODOS 
 
A longitudinal study was conducted from May 2008 to 
December 2009. All prescriptions from the ICU of a private 
hospital in the city of Aracaju (Brazil) were assessed. The hospital 
studied serves about 9,500 patients/year, representing 0.5% of the 
total population of the State. The ICU has 20 beds with 127 
employees, including 36 doctors and 12 nurses. This unit receives 
patients who require intensive care, such as postoperative and 
those with chronic degenerative diseases that frequently use a 
large variety of medicines for a long period of time.  
 
Data Collection 
Demographic data of each patient (name, age, gender) 
were collected from medical records (nursing evolution and 
medical assessment). The identities of patients and prescribers 
have been kept confidential. This study was approved by the 
Ethics Committee for Research of Universidade Federal de 
Sergipe.  
 
Prescribing patterns  
Total number of medicines were analyzed, as well as 
those most widely used and the presence of polypharmacy. 
Polypharmacy was defined as multiple use of five or more 
medications (Flores, Mengue, 2005; Linjakumpu et al., 2002). In 
order to identify substances and dosages from trade names, 
Guanabara Therapeutic Dictionary was used (Korolkovas, Ferrira, 
2007). The active principles present in each pharmaceutical 
specialty were listed and classified according the Anatomical-
Therapeutical-Chemical Classification System (ATC) (World 
Health Organization, WHO). 
 
Drug Interactions identification and management 
Data collected were assessed according to the 
combinations of drugs observed within 24 hours. Topical 
medicines, eye medicines, herbal medicines, oxygen inhalation, 
parenteral nutrition, enteral nutrition and enemas were excluded. 
In this study, DI were assessed by four sources of 
reference information: Stockley (2007), Medscape® (2010), 
Epocrates® (2010) and Micromedex® (2010) databases. These 
bases were selected due to data availability on the DI quality of 
information (excellent, good, fair and poor) and severity of the 
interaction (severe, moderate and light). All these variables were 
used to the calculation of the DI classification system. 
DI were identified in two steps. First, two pharmacists 
(TNGA and CCS) ranked DI regarding their level of importance, 
according to the method described by Tatro (2009). According to 
the information contained in databases about the severity and 
quality of documentation found, a numerical value was assigned. 
In this study, potentially significant DI were those with clinical 
value ranging from 1 to 3, highly significant DI were those with 
clinical value ranging 1 or 2, corresponding to severe or moderate 
intensity and established or probable evidence.  In the second step, 
all patients with DI identified and ranked as clinically relevant, in 
at least three databases, were assessed by the pharmacist to 
identify signs and symptoms due to DI. Hence, patient records and 
laboratory tests were reviewed in order to gather the information 
required to perform the interventions.  Regarding pharmacist DI 
management, when a clinically relevant DI was confirmed, a 
written warning was generated in the form of a report, intended for 
the prescribing physician or the nursing staff. The reports were 
interventions developed by the clinical pharmacists, describing the 
effect, mechanism and severity of DI, as well as reference to a 
previous clinical case described in the literature, proposing a 
conduct based on evidence. For the assessment of interventions 
effect, all patients were monitored regarding the adverse reactions 
from DI, observing if the recommendations provided in the reports 
were accepted, until discharge from the hospitalization unit. If 
necessary, the physician or the ICU nursing coordination was 
contacted to inform the need for more specific care for that patient. 
Statistical analysis was performed using the software Statistical 
Package for Social SciencesTM (SPSS) version 15.0 for Windows. 
Descriptive statistics were used to prescribing patterns and 
demographic variables. The chi-square test was used for 
associations between demographic variables and the presence of 
DI. The confidence interval of 95% was used to measure the 
strength of association between variables and a p-value < 0.05 was 
considered significant. 
 
RESULTS 
 
In the study 6,085 prescriptions of 213 patients were 
analyzed, of which 175 (2.9%) had at least one clinically relevant 
DI. In this analysis there was a predominance of female patients 
(n=113, 55.4%), although, there was no statistically significant 
association between DI and the frequency of women (χ2 = 61.01, 
p>0.1). In the study group, the average age was 66 (±7.0) (Table 1) 
and association was found between the number of DI and age 
increase (χ2= 532.55, p<0.05). Although there has been less simple 
frequency of prescriptions with polypharmacy from 2008 to 2009, 
the percentage of these prescriptions with multiple medications has 
remained high. However, there was a decrease in the number of DI 
from 2008 (133) to 2009 (80), around 40%. Moreover, significant 
association was found (χ2= 209.36, p<0.005) between the number 
of medications and the degree of severity between the observed 
DI. Finally, an increase of 19% of interventions accepted by 
physicians from 2008 to 2009 was observed, with a significant 
association (χ2 = 7.64, p<0.005) between interactions identified 
and resolved by the clinical pharmacist. The major clinical 
managements were identified: monitoring of signs and symptoms 
of DI (92, 43.2%), monitoring of therapeutic response (86, 40.3%), 
adjusting the time of administration (08; 3.7%), avoiding the 
combination of medications (22; 10.3%) and replacing it with 
other medications (05; 2.3%). 
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Table 1: Distribution of study population according to socio-demographic and pharmacotherapeutic aspects in the ICU of a private hospital (Aracaju-SE), from 
May 2008 to December 2009. 
 
Demographic characterization f (%) 
 2008  2009 
Gender   
Female 73 (55.4) 45 (56.3) 
Male 60 (44.6) 35 (43.7) 
Age   
≥60 83 (62.4) 54 (67.5) 
≥60 50 (37.6) 26 (32.5) 
Number of Prescriptions   
Assessed prescriptions 2,379 (100) 3,706 (100) 
Prescriptions with interaction  106 (4.5) 69 (1.9) 
Number of medicines per prescription   
1-4 1 (0.9) 0 (0.0) 
5-8  11 (10.4) 3 (4.3) 
9-12 23 (21.7) 18 (26.1) 
13-16 39 (36.8) 28 (40.6) 
17-20 29 (27.4) 18 (26.1) 
21-24 3 (2.8) 2 (3.0) 
Number of interactions  
Total 133 (100) 80 (100) 
Mechanism of interactions   
Pharmacokinetic 64 (48.1) 38 (47.5) 
Pharmacodynamic 66 (49.6) 37 (46.3) 
Unknown 3 (2.3) 5 (6.3) 
Severity of interactions  
Moderate 112 (84.2) 66 (82.5) 
Major 21 (15.8) 14 (17.5) 
Number of interventions   
Accepted 71 (53.4) 58 (72.5) 
Not accepted 62 (46.6) 22 (27.5) 
 
 
Table 2: Distribution of medicines used by the studied population, according to the ATC classification, at the ICU of a private hospital (Aracaju-SE), from 
May 2008 to December 2009.  
 
Major classes and subgroups ATC Code f (%)   
  2008 2009 Total 
Alimentary tract and metabolism A 320 (21.8%) 250 (25.4%) 570 (23,22%)  
Antacids/Antiulcer drugs/Antiflatulents  A02 103 68 171 
Antispasmodic, Anticholinergic and Propulsive Agents A03 92 77 169 
Drugs used in Diabetes A10 76 66 142 
Vitamins A11 22 14 36 
Nervous system N 275 (18.7%) 211 (21.4%) 486 (19.80%) 
Anesthetics N01 52 24 76 
Analgesics N02 86 96 182 
Antiepileptics N03 47 33 80 
Psycholeptics N05 81 47 128 
Cardiovascular system C 262 (17.8%) 182 (18.5%) 444 (18.09%) 
Cardiac drugs C01 83 58 141 
Diuretics C03 88 48 136 
Inhibitors of the Renin-angiotensin System                                                   C09 36 41 77 
Hypolipidemic agents C10 21 11 32 
Respiratory system R 205 (14%) 108 (10.9%) 313 (12.75%) 
Nasal preparations R01 79 47 126 
Anti-asthmatics R03 120 51 171 
General anti-infectives for systemic use J 169 (11.5%) 119 (12 %) 288 (11.72%) 
Antibacterials for systemic use J01 150 103 253 
Antimycotics for systemic use J02 19 15 34 
Blood and blood forming organs B 140 (9.5%) 53 (5.4%) 193 (7.85%) 
Antithrombotic agents B01 94 37 131 
Blood substitutes and perfusion solution B05 41 16 57 
Systemic hormonal preparations, excluding sex hormones and insulins H 76 (5.2%) 54 (5.5%) 130 (5.30%) 
Musculoskeletal system M 8 (0.6%) 5 (0.5%) 13 (0.53%) 
Dermatologic agents D 8 (0.6%) - 8 (0.83%) 
Genitourinary system and sex hormones G 2 (0.1%) 3 (0.3%) 5 (0.21%) 
Antineoplastics and agents Immunomodulators L 2 (0.1%) 1 (0.1%) 3 (0.12%) 
Various V 2 (0.1%) - 2 (0.08%) 
Total  1469 (100%) 986 (100%) 2455 (100%) 
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The average of different medications per prescription 
was 14.0 ± 3.8. Table 2 provides a detailed description of the most 
used medications, according to the anatomical (Level 1) and 
therapeutical (Level 2) classification of the ATC. Among the most 
prescribed therapeutic classes, medications that act in the 
alimentary tract and metabolism are highlighted (23.22% - 
antacids/antiulcer drugs/antiflatulents); nervous system (19.80% - 
analgesics) and the cardiovascular system (18.09% - cardiac drugs 
and diuretics).  Table 3 provides a detailed description of DI 
identified with regard to mechanism and severity degree. The 
number of clinically relevant DI per prescription ranged from one 
to five with an average of 1.22. Of these, the most frequent DI in 
the study sample were Bromopride x ipratropium (38; 29.5%), 
insulin x hydrocortisone (17; 13.2%) and dexamethasone x 
phenytoin (17; 13.2%). 
 
DISCUSSION 
 
This study showed a predominance of female patients, 
this is corroborated by the literature that demonstrates the 
feminization in the Brazilian population aging (Flores, Mengue, 
2005; Dias Junior et al., 2006). Although Lima and Cassiani 
(2009) claim that females receive  more  medicines  and  are  more 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
likely to DI, this study found no association between the frequency 
of women and DI. 
In Brazil there has been a considerable growth in the 
population of Brazilian citizens with more than 60 years old 
(Cruciol-Souza, Thomson, 2006). In this study, an association 
between elderly people and the presence of DI was found (Lima, 
Cassiani, 2009; Bleich et al., 2009; Blix et al., 2008). According to 
the literature, age is a risk factor for DI, since elderly people have 
more physiological alterations and chronic health conditions that 
favor a longest ICU stay and increased use of drugs/day, enabling 
the prescription of more complex pharmacotherapeutic 
combinations (Hamms et al., 2008; Lima, Cassiani, 2009). 
In this study, the average of medications per prescription 
was similar to that found by Hammes and colleagues (2008) and 
Ibáñez (2009). The existence of multiple diseases in patients 
hospitalized in ICUs has contributed significantly to the increased 
use of polypharmacy in recent years, which favors a higher 
incidence of DI and therapeutic duplicity (Cruciol-Souza, 
Thomson, 2006; Bleich et al., 2009; Locatelli et al., 2010). Thus, 
the analysis and monitoring of prescriptions by the clinical 
pharmacist in the ICUs could be an important safety collaborator 
for the patient. Unlike the results found in international studies 
conducted in hospitals (Blix  et al., 2008; Cremades et al., 2009), 
Table 3: Main drug interactions clinically important, drugs used by the studied population at the ICU of a private hospital (Aracaju-SE), from May 2008 to 
December 2009.  
Interactions Repetitions Severity Mechanism Interaction Effects Intervention Report Significance* 
Bromopride x 
ipratropium 38 (29.5%) Moderate Dynamic 
Effects of bromopride on gastrointestinal 
motility are antagonized by anticholinergic 
drugs 
Accepted (20) 
Not accepted   (18) NA 
Insulin x 
hydrocortisone 17 (13.2%) Moderate Dynamic 
 Hydrocortisone decreases effects of insulin by 
pharmacodynamic antagonism 
Accepted (11) 
Not accepted (6) NA 
Dexamethasone x 
phenytoin 17 (13.2%) Moderate Kinetic 
Concurrent use of dexamethasone and phenytoin 
may result in decreased dexamethasone 
effectiveness 
Accepted (8) 
Not accepted (9) Grade 2 
Furosemide x 
hydrocortisone 11 (8.5%) Moderate Kinetic 
Concurrent use of furosemide and 
hydrocortisone may result in hypokalemia 
Accepted (7) 
Not accepted (4) NA 
Moxifloxacin x 
amiodarone 9 (7.0%) 
Major 
 Dynamic 
Concurrent use of amiodarone and moxifloxacin 
may result in an increased risk of QT interval 
prolongation 
Accepted (7) 
Not accepted (2) Grade 1 
AAS x furosemide 8 (6.2%) Moderate Kinetic  AAS decreases effects of furosemide. 
Accepted (4) 
Not accepted (4) Grade 2 
Dexamethasone x 
insulin 8 (6.2%) Moderate Dynamic 
Dexamethasone decreases effects of insulin by 
pharmacodynamic antagonism 
Accepted (3) 
Not accepted (5) NA 
Domperidone x 
ipratropium 8 (6.2%) Moderate Dynamic 
Domperidone may antagonize the effects of 
anticholinergic drugs on gastric motility 
Accepted (7) 
Not accepted (1) NA 
Fluconazole x 
phenytoin 7 (5.4%) Moderate Kinetic 
Concurrent use of fluconazole and phenytoin 
may result in an increased risk of phenytoin 
toxicity (ataxia, hyperreflexia, nystagmus, 
tremors) 
Accepted (4) 
Not accepted (3) Grade 2 
Amiodarone x fentanyl 6 (4.7%) Major Kinetic 
Concurrent use of amiodarone and fentanyl may 
result in cardiac toxicity (low cardiac output) 
and an increased risk of fentanyl toxicity 
(central nervous system depression, respiratory 
depression). 
Accepted (5) 
Not accepted (1) Grade 1 
* Classification criteria TATRO, 2009. Note that the lower the value the greater the clinical significance of the interaction. 
* NA = when the degree of significance is not in the reference. 
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the majority of prescribed drugs was alimentary tract and 
metabolism agents, followed by drugs for the nervous and 
cardiovascular systems. However, the data are similar to other 
studies conducted in ICUs in Brazil (Hamms et al., 2008; Lima, 
Cassiani, 2009). The use of medications that act in the alimentary 
tract and metabolism has been a common practice in stress ulcer 
prophylaxis in critically ill patients, since several diseases that 
require hospitalization in the ICU are directly associated with 
gastric mucosal lesions (Araujo et al., 2010; Pompilio,   
Cerconello, 2010). This fact may explain the findings in this study.  
The number of DI identified in this study was lower than 
in similar studies (Reis, Cassiani, 2011; Lima, Cassiani, 2009; 
Cruciol-Souza, Thomson, 2006). According to Saverno (2009) and 
Abarca (2004) researchers usually record all DI detected by 
software, without worrying about their clinical relevance. As a 
result, an overestimation occurs in the identification of 
theoretically found DI, without reflecting the clinical practice 
reality. Tatro (2009) argues that differences between the results 
obtained and literature data may be associated with different 
concepts of clinical relevance used by each member of the 
assessment group, and with databases used by DI identification 
software. 
Previous studies confirm that the majority of DI 
identified was also of moderate severity (Lima, Cassiani, 2009; 
Bleich et al., 2009; Aspinall et al., 2007). After the pharmaceutical 
interventions, the number of moderate DI halved in this study. 
However, the percentage of interactions of moderate severity was 
maintained from one year to another, similarly to other studies in 
the literature (Reis, Cassiani, 2011; Dinesh et al., 2007). 
Therefore, it is critical that the clinical pharmacist monitors the 
specific cases of DI, managing pharmacotherapy when necessary, 
and minimizing the deterioration of the patient's clinical condition. 
In the first year of this study most of the DI identified was 
pharmacodynamics interactions, as confirmed by the study of 
Dinish (2007), in a teaching hospital at Nepal. After the 
pharmacist’s interventions, there was an inversion in the 
predominant mechanism of DI found, with higher frequency of 
pharmacokinetic interactions. In a study conducted by Lima 
(2009), at the ICU of a teaching hospital in Brazil, a greater 
frequency of this mechanism was also found. According to Reis 
(2011), adverse events can be determined by the potential for 
pharmacokinetic interactions that inhibit the metabolism of drugs. 
Given this profile of interactions, prevention measures for patient 
safety in the ICU should include strategies as the adjustment of 
medications dose, observation and clinical monitoring of the 
patient in order to detect or prevent adverse events.  
An increasing number of pharmacist’s recommendation 
reports accepted by the prescribing physician were observed in this 
research, contributing to the reduction of DI from one year to the 
other. In the study of Grizzle et al. (2007), it was observed that 
most interventions were accepted and 89.4% of clinically 
significant DI were replaced by the prescriber. According to 
Bleich (2009), DI assessment, made by the clinical pharmacist, 
seems to improve the quality of prescriptions in hospitals. Thus, it 
is essential that risk factors and clinical relevance of DI be 
identified and disseminated among health professionals, providing 
the choice of safe dosage regimens, improvement of quality of 
care and prevention of harm to the patient. 
As for the clinical management, the most frequent 
intervention was monitoring of signs and symptoms, and this is 
corroborated by the literature (Lima, Cassiani, 2009; Vonbach et 
al., 2007). To Locateli (2010), most of the DI can be controlled by 
other means than the suspension of drugs combination, such as 
dose adjustment and monitoring of possible adverse events, i.e., 
the individualized assessment of risk and benefit for each DI. In 
this sense, the pharmacist can disseminate information about 
medicines to multidisciplinary team, monitoring the possible 
effects of DI and assisting ICU physicians in the pharmacotherapy 
effectiveness and safety. 
Benefits and limitations were observed in this study. 
Among the benefits, it is possible to mention the sampling 
dimension and standardization of the method used for DI 
detection, with the use of four sources of reference information, 
increasing data sensitivity and the degree of documentation, which 
are important features for clinical relevance. Another advantage 
was the clinical investigation of DI with patients, which 
contributed to the effect and acceptance of pharmacist’s 
interventions performed during the assessment.  
On the other hand, this study has some limitations. First, 
some data were not collected, as total number of admissions in the 
ICU, duration of patient stay and absence of clinical outcomes 
assessment. Also, it should be noted that the light severity DI were 
not considered, for their lack of relevance in clinical practice. This 
fact may have contributed to the underestimation of the number of 
identified DI. Another limitation is related to the study in a single 
ICU, which hinders the generalization of results. 
 
CONCLUSION 
 
The results of this study suggest that pharmacist’s 
contribution may have reduced the identified DI. Moreover, the 
pharmacist management might have enabled greater familiarity of 
physicians regarding clinically relevant DI, optimizing the quality 
of prescriptions, especially in the ICU. In this context, the effect of 
clinical pharmacist interventions in a multidisciplinary team may 
promote health, preventing and monitoring adverse events, 
intervening and contributing for pharmacotherapy effectiveness 
and patient safety. 
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